Literature DB >> 15549315

[Regression of germ cell tumors after chemotherapy].

V Loy1, U Klenk, J Linke.   

Abstract

Today the treatment of gonadal germ cell tumors is standardized. The cisplatin containing chemotherapy and the multi-modal therapy strategies have increased the rate of successful treatment enormously. Germ cell tumors are almost always treated surgically. Following the rare, primary chemotherapy, the residual tumor must be classified according to the WHO as accurately as possible. A binding system for the documentation of tumor regression does not exist. The diagnostic retroperitoneal lymphadenectomy is also rare. Here as well, the classification is performed according to the WHO and the TNM classification. The examination of the tissue samples from a retroperitoneal lymphadenectomy after chemotherapy is problematic. The morphology is often bizarre, preparatory and terminological standards do not exist. Is there still vital tumor present then it can most often be diagnosed as a teratoma. In that case a classification takes place as to whether it is "mature" or "immature". If a tissue sample contains other differentiations, the classification is performed in detail according to the WHO classification of germ cell tumors. Sarcomas or carcinomas must be reliably distinguished and classified, as they lead to different therapeutic consequences. The terminology must be defined in a binding manner between both the pathology and the clinic, due to the lack of global definitions.

Entities:  

Mesh:

Year:  2004        PMID: 15549315     DOI: 10.1007/s00292-004-0721-6

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  19 in total

Review 1.  Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM).

Authors:  S Krege; R Souchon; H J Schmoll
Journal:  Eur Urol       Date:  2001-10       Impact factor: 20.096

2.  [Diagnosis and therapy of testicular tumors].

Authors:  P Albers
Journal:  Urologe A       Date:  2002-07       Impact factor: 0.639

3.  Spindle cell tumors resected from male patients with germ cell tumors. A clinicopathologic study of 14 cases.

Authors:  T M Ulbright; H Michael; P J Loehrer; J P Donohue
Journal:  Cancer       Date:  1990-01-01       Impact factor: 6.860

4.  The significance of atypia within teratomatous metastases after chemotherapy for malignant germ cell tumors.

Authors:  D D Davey; T M Ulbright; P J Loehrer; L H Einhorn; J P Donohue; S D Williams
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

5.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Prognostic factors for relapse in stage I testicular seminoma treated with surveillance.

Authors:  P Warde; M K Gospodarowicz; D Banerjee; T Panzarella; L Sugar; C N Catton; J F Sturgeon; M Moore; M A Jewett
Journal:  J Urol       Date:  1997-05       Impact factor: 7.450

7.  [Testicular tumors. Mortality and recurrence after inadequate therapy].

Authors:  P Albers; K Dommer; S C Müller
Journal:  Urologe A       Date:  1998-11       Impact factor: 0.639

8.  Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture.

Authors:  L H Einhorn
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

Review 9.  Choriocarcinoma-like lesions in patients with testicular germ cell tumors. Two histologic variants.

Authors:  T M Ulbright; P J Loehrer
Journal:  Am J Surg Pathol       Date:  1988-07       Impact factor: 6.394

10.  Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; H Dienemann; M Weiss; M Kriegmair; U Löhrs; W Wilmanns
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.